Lithotripsy Devices Market Size, Share & Growth Forecast 2026-2031

The global lithotripsy devices market is estimated at USD 1.08 billion in 2026 and is projected to reach USD 1.39 billion by 2031, growing at a CAGR of 5.2% across 2026-2031.

Growth is being shaped by a gradual shift from stand-alone shock-wave treatment toward endoscopic stone management, particularly flexible ureteroscopy paired with higher-performance laser systems. Extracorporeal shock wave lithotripsy remains important because it is non-invasive and suitable for selected renal and ureteral stones, but intracorporeal technologies capture increasing value through higher procedure intensity, laser-console upgrades, fibers, probes, suction-enabled systems, and operating-room integration. The resulting market is a mixed replacement and technology-upgrade opportunity rather than a simple procedure-volume market.

Market Drivers

• Persistent kidney-stone burden sustains procedural demand

Urinary stone disease is common and recurrent, creating a durable clinical requirement for stone-fragmentation equipment. NIDDK estimates indicate that kidney stones affect roughly 11% of men and 6% of women in the United States during their lifetime. Recurrence is clinically important, and treatment pathways commonly include shock-wave lithotripsy, ureteroscopy with laser fragmentation, or percutaneous nephrolithotomy depending on stone size, location, composition, anatomy, and prior treatment response. This recurring patient base supports both replacement of installed lithotripters and expansion of flexible endourology capacity in hospitals and ambulatory surgical centers.

• Endourology upgrades are increasing laser-platform value

Laser lithotripsy has become a core component of modern ureteroscopic stone management. Olympus reported continued sales growth for its SOLTIVE SuperPulsed Laser System in fiscal 2025 and described the platform as the leading thulium-fiber lithotripsy system in its launched regions. Boston Scientific continues to commercialize its Lumenis Pulse 120H platform with MOSES pulse modulation, while Quanta System, KARL STORZ, LISA Laser Products, and other vendors maintain active urology-laser portfolios. The competitive focus is moving toward higher ablation efficiency, reduced retropulsion, smaller fibers, pulse shaping, digital feedback, and platforms that can serve both stone and soft-tissue procedures.

• Combined fragmentation and suction systems improve workflow

Intracorporeal ultrasonic and ballistic systems remain relevant in percutaneous and high-burden stone procedures, especially where simultaneous fragmentation and evacuation can shorten stone-clearance workflow. EMS markets the Swiss LithoClast Trilogy platform combining ballistic and ultrasonic energy with suction, while Olympus supports ultrasonic and pneumatic stone-management technologies alongside laser systems. These platforms are smaller in unit volume than mainstream laser consoles but retain value in complex stone procedures and contribute to recurring probe and accessory demand.

Market Restraints

• Long capital-equipment replacement cycles limit annual console demand in mature hospital markets.

• Treatment choice depends on stone characteristics, anatomy, local expertise, and reimbursement economics.

• High-performance laser systems compete for budgets with endoscopes, imaging, and disposable-accessory upgrades.

• Lower-cost regional suppliers intensify pricing pressure in conventional extracorporeal shock-wave systems.

Global Lithotripsy Devices Market Segment Analysis

• By Modality

Intracorporeal laser lithotripsy is the largest value segment because modern ureteroscopy increasingly pairs reusable or single-use ureteroscopes with holmium:YAG or thulium-fiber energy. The segment is expected to expand at roughly 6.4% annually through 2031, faster than the overall market, supported by console upgrades and higher-value fiber consumption. Extracorporeal shock-wave lithotripsy remains a meaningful installed-base market, particularly where non-invasive outpatient treatment is preferred. Ultrasonic, pneumatic, ballistic, and combination systems serve percutaneous and complex stone-removal workflows and provide an additional equipment and consumables layer.

• By Application and End User

Kidney and ureteral stones dominate device utilization, with bladder stones forming a smaller urological application and biliary or pancreatic stones representing selected endoscopic uses for intracorporeal systems. Hospitals remain the largest end-user group because they concentrate operating rooms, imaging, anesthesia, and complex percutaneous procedures. Ambulatory surgery centers and specialist urology centers are gaining relevance in markets where ureteroscopy and selected shock-wave procedures can be performed efficiently outside large tertiary hospitals.

Regional Analysis

North America represents the largest value pool because of high ureteroscopy utilization, strong adoption of premium laser platforms, and a large ambulatory-surgery infrastructure.

Europe maintains a broad installed base of shock-wave and laser equipment, supported by established German, Swiss, Italian, and other European manufacturers. Asia Pacific is expected to grow fastest as China and India expand urology capacity and domestic manufacturers increase product sophistication. Latin America and the Middle East and Africa remain selective capital-equipment markets, with procurement weighted toward high-throughput tertiary centers and cost-effective shock-wave systems.

Competitive Environment

Competition is divided between diversified endourology suppliers and focused lithotripsy specialists. Boston Scientific and Olympus compete across laser platforms, fibers, stone retrieval, and broader urology workflows. Dornier MedTech and STORZ Medical remain strongly associated with extracorporeal shock-wave systems, while EMS, Quanta System, KARL STORZ, Richard Wolf, Medispec, Potent Medical, Allengers, and other specialists compete by modality and geography. Product differentiation increasingly depends on pulse control, treatment efficiency, integrated suction, service support, energy-source flexibility, regulatory coverage, and the ability to support complete stone-management pathways.

Recent Developments

• May 2025: Olympus reported more than 10% fiscal-year growth for SOLTIVE in launched regions and continued geographic expansion of the thulium-fiber platform.

• 2025-2026: Boston Scientific continued commercialization of the Lumenis Pulse 120H system with MOSES 2.0 technology and a broad lithotripsy fiber portfolio.

• June 2026: STORZ Medical highlighted current evidence supporting optimized shock-wave delivery and ongoing relevance of extracorporeal lithotripsy in selected renal stones.

Market Outlook

Through 2031, value growth is expected to concentrate in laser lithotripsy, upgraded pulse-control systems, higher-power compact platforms, and integrated fragmentation-suction workflows. Extracorporeal shock-wave lithotripsy will remain an important option rather than disappearing, but its growth profile is likely to trail endoscopic technologies. Vendors with broad regulatory coverage, strong clinical training, fibers and probes that create recurring revenue, and complete stone-management portfolios are positioned to capture a greater share of equipment refresh cycles.

Global Lithotripsy Devices Market Scope: